drugset
drugset / Trial / NCT02341209

Doxycycline for the Treatment of Cutaneous T-Cell Lymphoma

NCT02341209 ↗

Phase 2 Terminated 1 enrolled Rochester General Hospital
NaSingle-groupOpen-labelTreatment

Summary

This study looks at the efficacy of Doxycycline for the treatment of Cutaneous T-cell Lymphomas.

Timeline

Start
2018-02-06
Primary completion
2021-02-06
Completion
2021-02-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Doxycycline Small molecule 400 mg —

Indications

Sezary syndrome mycosis fungoides